ÖTÖzde Nisa Türkkan

Özde Nisa Türkkan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Özde Nisa Türkkan has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Awareness, perceptions, and practices regarding transition to adult care for nephropathic cystinosis in Türkiye: a nationwide cross-sectional survey of pediatric nephrologists

    by Yeşim Özdemir Atikel, Sevcan A. Bakkaloğlu, Alev Yılmaz, Aslı Çelebi Tayfur, Aslı Kavaz Tufan, Aslıhan Kara, Ayşe Seda Pınarbaşı, Aysun Çaltık Yılmaz, Bahriye Atmış, Bedriye Nuray Alpman, et al.

    Background: Nephropathic cystinosis is a rare multisystem disorder in which transition from pediatric to adult care is particularly a vulnerable period because of lifelong treatment demands and the need for sustained multidisciplinary follow-up. We aimed to assess awareness, perceptions, and self-reported transition practices among pediatric nephrologists in Türkiye caring for patients with nephropathic cystinosis. Methods: We conducted a nationwide descriptive cross-sectional web-based survey of pediatric nephrologists in Türkiye who had longitudinally followed at least one patient with nephropathic cystinosis. A 59-item questionnaire covering awareness, perceptions, and self-reported practices was administered via Google Forms, and responses were analysed descriptively at the item level. Results: In this nationwide descriptive cross-sectional web-based survey, 48 pediatric nephrologists participated. Respondents worked mainly in university hospitals (47.9%) and training and research hospitals (39.6%) and had a median of 14 years of pediatric nephrology experience (IQR 6–17). Although 66.7% distinguished transition from transfer, familiarity with cystinosis-specific transition models was limited; only 16.7% had ever applied a structured model and 8.3% reported a written transition plan in their center. The most frequently perceived challenges were treatment non-adherence (89.6%) and disruption of multidisciplinary follow-up (87.5%). Most respondents reported marked differences between pediatric and adult services, and the median recommended age for initiating transition planning was 17.5 years (IQR 17–18). Overall, 91.7% supported the development of a national transition model (58.3% considered it definitely necessary and 33.3% necessary but difficult to implement without external support). Conclusions: Among pediatric nephrologists in Türkiye, awareness of transition-related risks in nephropathic cystinosis was high, but structured transition practices were uncommon and initiation of transition planning was generally recommended at a later age than suggested by current guidance. These findings indicate an implementation gap and support the development of a feasible national transition framework that can be adapted to local resources.

  • Open Access

    Clinical course of proteinuria due to cubilin variants: a large multicenter pediatric cohort

    by Neslihan Cicek, Ceren Alavanda, Ayse Seda Pınarbası, Aylin Inal, Bahriye Atmıs, Secil Kezer, Mehtap Akbalik Kara, Okan Akaci, Serim Pul, Sevcan Hatipoglu, et al.

    Introduction: We aimed to evaluate the clinical and genetic characteristics and clinical course of children with persistent proteinuria associated with CUBN variants. Methods: Forty-eight children with CUBN variants from 15 pediatric nephrology centers were included. Patients’ characteristics, serum creatinine, albumin, hemoglobin, vitamin B12 levels, urinalysis, spot urine protein/creatinine (uPCR), microalbumin/creatinine (uACR), beta-2 microglobulin/creatinine (uBMCR) ratios, estimated glomerular filtration rates (eGFRs), treatments, kidney biopsies, and genetic findings were evaluated. Results: All patients had normal serum albumin and creatinine and preserved eGFR. There was no significant change in eGFR between the first and last visits ( p = 0.15), whereas uPCR was lower at the last visit ( p = 0.001). Kidney biopsy was performed in 13 (27%); light microscopy was normal in all except one patient with focal segmental glomerulosclerosis (FSGS). Thirty-five patients (72.9%) had ACEi/ARB therapy, which was discontinued in 21 patients without subsequent worsening of proteinuria. Overall, 26 distinct CUBN variants were identified, predominantly in the C-terminal region. The most frequent variant was c.10102A > G (p.Met3368Val). Variant types included 15 (57.7%) missense, 7 (27%) nonsense, 3 (11.5%) splicing, and 1 (3.8%) frameshift variants. Conclusions: In this multicenter, large pediatric cohort, proteinuria associated with CUBN variants generally followed a benign course over short to mid-term follow-up even without sustained ACEi/ARB therapy. Embedding targeted CUBN testing into the evaluation of children with asymptomatic proteinuria and normal kidney function may reduce unnecessary kidney biopsies and prolonged medication, while improving family counseling. We outline a stepwise care pathway → early genetic screening → conservative monitoring with periodic eGFR and proteinuria assessment → consideration of ACEi/ARB discontinuation and recommend prospective validation and cost-effectiveness studies.


  • Predictors of kidney survival in children with autosomal recessive polycystic kidney disease

    by Neslihan Çiçek, İbRahim Gökçe, Ceren Alavanda, Serçin Güven, Mehtap Kaya, Serim Pul, Özde Nisa Türkkan, Nurdan Yıldız, Pınar Ata

    Background The phenotype of autosomal recessive polycystic kidney disease (ARPKD) can be quite variable: some patients progress to end-stage kidney disease (ESKD) in infancy, while others may not require kidney replacement therapy (KRT) until later childhood or adolescence. This study aimed to evaluate clinical, biochemical, imaging, and genetic findings that may influence kidney prognosis in pediatric patients with ARPKD. Methods The patients diagnosed before birth or in the first month were classified as perinatal presenters and later than 1 month as non-perinatal presenters. Additionally, groups were formed based on estimated glomerular filtration rate (eGFR) at the last visit and variant types. Results Seventeen patients (8 male, 9 female) were enrolled in the study. Kidney survival rates at 5 years was 71.4% in the perinatal group, whereas it was 100% in the non-perinatal group. The early height-adjusted kidney dimension (haKD) was positively correlated with perinatal presentation and antenatal diagnosis. At the last follow-up, the mean eGFR was significantly lower in the truncating group with four patients (23.5%) progressing to stage-5 chronic kidney disease (CKD). Conclusions The kidney survival rate is lower in patients with early presentation. Initial low eGFR and severe variants are important predictors of kidney survival. Additionally, early high haKD may be associated with poor kidney outcome. Further studies with larger patient populations and long-term follow-up are necessary to better understand the prognosis of pediatric patients with ARPKD.

  • Open Access

    Does cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improve survival in children with desmoplastic small round cell tumors? First experiences from Turkey

    by Kıvılcım Cerit Karadeniz, Nurşah Eker, Ahsen Karagözlü Akgül, Dilek Gül, Özde Nisa Türkkan, Ayten Ceren Bakır, Ali Eyvazov, Gürsu Kıyan

    Objective: Desmoplastic small round cell tumor (DSRCT) is a rare form of highly aggressive sarcoma and despite multimodal therapy, mortality still remains high. The aim of the study is to review our experience in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in children with DSRCT. Patients and Methods: A retrospective review of patients with DSRCT followed in our institution between January 2020-January 2024 was performed. Demographics, radiological imaging, histopathology results, cytogenetic analyses, chemotherapy/radiotherapy protocols, operative data and outcomes were analyzed. Results: Three patients with DSRCT were identified. The median age was 13.3 years (12-16 years). HIPEC was performed after CRS in two patients, while HIPEC procedure could not be applied in one patient with unresectable tumor. One patient underwent reoperation/re-HIPEC for recurrence after seven months. One patient had the diagnosis after complete removal of the tumor. Patient required peritonectomy and HIPEC as a second operation due to peritoneal recurrence. The patients who underwent CRS and HIPEC are still alive for 33 and 34 months since initial diagnosis, nevertheless the patient who had an unresectable tumor died after 8 months. Conclusion: Cytoreductive surgery and HIPEC may be considered as a safe and feasible treatment option in children with DSRCT in experienced centers.

  • Open Access

    Pediatri Polikliniklerinde Sık Görülen Vakalar

    by Yahya Gül, Şeyhan Kutluğ, Esra Dişçi, Bahtınur Yener, Mahmut Cesur, Elif Arık, Hasan Kapaklı, Gaye İnAl, Feyat Tunç, Nergiz Kendirci, et al.

    Ömrünü eğitime ve tıp bilimine adamış, pediatri alanında kendi eğitimini tamamlayan ve hala sürdüren yazarlarımız ile iki yıldır süren çalışmalarımızın meyvesi olan kitabımız için çok mutluyuz. Yedi yaşından beri gece gündüz demeden çalışan, pediatri uzmanlığını ve yan dalını hakkıyla tamamlamak için çok emek harcayan arkadaşlar, tecrübelerini ve öğrendiklerini eğitime yeni başlayan meslektaşlarına aktarmak için bir kılavuz olacak bu kitabı hazırladık. Bu kitabın; pratisyen hekim, pediatri asistanları ve uzmanlarına klinik pratikte en sık karşılaşacakları hastalıkların tanısı, kliniği ve tedavisi konusunda hızlıca bilgilere ulaşabilmeleri açısından çok büyük kolaylık sağlayacağına inanıyoruz. Bu nedenle acillerde, polikliniklerde ve servislerde sıkça başvurulan bir kitap olacağını düşünüyoruz.

  • Open Access

    Çocuklarda Hipertansiyon Risk Faktörü Olarak Obezite ve Metabolik Sendrom

    by Bağdagül AKSU, Zeynep Yuruk Yi̇ldi̇ri̇m, Alev Yilmaz, Cemile Pehli̇vanoğlu, Özde Nisa Türkkan, Aslı Derya KARDELEN AL, Ilmay Bi̇lge, Aydan Şi̇ri̇n, Sevinç Emre

    Hipertansiyon (HT), çocuklarda giderek artan önemli bir sağlık sorunudur. Son 20 yıl içinde çevresel ve sosyal faktörlerdeki değişiklikler, daha az fiziksel aktivite, hızlı beslenme alışkanlıkları, obezite ve metabolik sendrom, HT gelişimini doğrudan etkilemektedir. Çalışmamızın amacı, 18 yıllık bir süreçte HT tanısıyla izlenen çocuklarda yıllar içinde obezite ve metabolik sendrom sıklığının artıp artmadığını belirlemektir. Ocak 2001-Aralık 2018 tarihleri arasında Çocuk Nefroloji Polikliniği’nde HT nedeni ile başvuran ve HT tanısı kesinleşen 377 hasta retrospektif olarak değerlendirildi. Hastalar, 2001-2009 döneminde başvuran hastalar (Grup I) ve 2010-2018 döneminde başvuran hastalar (Grup II) olmak üzere iki gruba ayrıldı ve iki grup obezite ve metabolik sendrom açısından karşılaştırıldı. Ortalama başvuru yaşı 11,4±4,5 yıldı. Hastaların %64’ü erkekti. Grup 2’deki hastaların yaş, VKİ, metabolik sendrom ve ailede hipertansiyon olma öyküsü Grup 1’den yüksekti. İki grup arasında obezite açısından fark yoktu (p>0,05). Çalışmamızın sonuçları, hipertansiyon tanısıyla izlediğimiz hastalarda son yıllarda 2009 ve öncesine göre hem VKİ’de hem de metabolik sendrom görülme oranında artış olduğunu göstermiştir. Bu değişiklikler, özellikle ergenlerde belirgindir. Çocuk ve ergenlerde sodyum alımının azaltılması ve yaşam tarzı değişikliği önerileriyle obezitenin önlenmesi, HT gelişiminin engellemesi ve tedavisinde ilk aşamayı oluşturur.

  • Open Access

    Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study

    by Mehmet Taşdemir, Nur Canpolat, Nurdan Yildiz, Gül Özçelik, Meryem Benzer, Seha Kamil Saygili, Emine Neşe ÖZKAYIN, Özde Nisa Türkkan, Ayşe BALAT, Cengiz Candan, et al.

    Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen. Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m(2)) or high (2-4 doses of 375 mg/m(2)) initial dose of rituximab and the steroid response. Clinical outcomes were compared. Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9-17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 +/- 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups. Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.